A detailed history of Cwm, LLC transactions in Compass Pathways PLC stock. As of the latest transaction made, Cwm, LLC holds 855 shares of CMPS stock, worth $7,301. This represents 0.0% of its overall portfolio holdings.

Number of Shares
855
Previous 855 -0.0%
Holding current value
$7,301
Previous $5,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 01, 2024

BUY
N/A
375 Added 78.13%
855 $7,000
Q3 2023

Oct 11, 2023

SELL
N/A
-1,720 Reduced 78.18%
480 $4,000
Q2 2023

Aug 03, 2023

BUY
$7.79 - $10.69 $9,348 - $12,828
1,200 Added 120.0%
2,200 $18,000
Q1 2021

Sep 15, 2021

BUY
$34.75 - $57.5 $34,750 - $57,500
1,000 New
1,000 $38,000
Q1 2021

Apr 27, 2021

SELL
$34.75 - $57.5 $34,750 - $57,500
-1,000 Closed
0 $0
Q4 2020

Sep 15, 2021

BUY
$32.0 - $59.2 $32,000 - $59,200
1,000 New
1,000 $38,000
Q4 2020

Jan 27, 2021

SELL
$32.0 - $59.2 $32,000 - $59,200
-1,000 Closed
0 $0
Q3 2020

Sep 15, 2021

BUY
$28.83 - $43.17 $28,830 - $43,170
1,000 New
1,000 $38,000
Q3 2020

Oct 19, 2020

SELL
$28.83 - $43.17 $28,830 - $43,170
-1,000 Closed
0 $0
Q2 2020

Sep 15, 2021

BUY
N/A
1,000 New
1,000 $38,000
Q2 2020

Jul 22, 2020

SELL
N/A
-1,000 Closed
0 $0
Q1 2020

Sep 15, 2021

BUY
N/A
1,000 New
1,000 $38,000
Q1 2020

Apr 28, 2020

SELL
N/A
-1,000 Closed
0 $0
Q4 2019

Sep 14, 2021

BUY
N/A
1,000 New
1,000 $38,000
Q4 2019

Jan 27, 2020

SELL
N/A
-1,000 Closed
0 $0
Q3 2019

Sep 14, 2021

BUY
N/A
1,000 New
1,000 $38,000
Q3 2019

Oct 22, 2019

SELL
N/A
-1,000 Closed
0 $0
Q2 2019

Sep 14, 2021

BUY
N/A
1,000 New
1,000 $38,000
Q2 2019

Jul 31, 2019

SELL
N/A
-1,000 Closed
0 $0
Q1 2019

Sep 02, 2021

BUY
N/A
1,000 New
1,000 $0

Others Institutions Holding CMPS

About COMPASS Pathways plc


  • Ticker CMPS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Care Facilities
  • Shares Outstandng 42,522,400
  • Market Cap $363M
  • Description
  • COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. Th...
More about CMPS
Track This Portfolio

Track Cwm, LLC Portfolio

Follow Cwm, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.